Cough Variant Asthma
Conditions
Keywords
cough variant asthma, chronic cough, fractional exhaled nitric oxide, impulse oscillometry, forced mid-expiratory flow
Brief summary
The aim of the research is to evaluate the clinical value of fractional exhaled nitric oxide(FeNO) ,impulse oscillometry(IOS) and mid-expiratory flow (MEF) in patients with cough variant asthma.
Detailed description
The present study has the following objectives: to evaluate the relationship between BHR and mid-expiratory flow, to assess the diagnostic accuracy of fractional exhaled nitric oxide，impulse oscillometry and mid-expiratory flow in CVA with special regard to its discriminating value between CVA and other causes of a chronic cough, to estimate prognostic value of BHR and fractional exhaled nitric oxide (FeNO) count in predicting response to asthma treatment.
Interventions
DIAGNOSTIC_TESTfractional exhaled nitric oxide(FeNO)
FeNO level was evaluated according to the American Thoracic Society (ATS)/ERS recommendations using a NIOX MINO analyzer (Aerocrine, Solna, Sweden) .Subjects were informed to deeply inhale NO-free air and immediately exhale in full via a mouthpiece at a constant flow rate (50 ml/s) for 10s.
DIAGNOSTIC_TESTimpulse oscillometry(IOS)
The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.
Sponsors
Zhujiang Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
age 18-65 years old. Cough as the sole or predominant symptom lasting for at least 8 weeks, with no radiographic evidence of lung diseases.
Exclusion criteria
treatment of any oral corticosteroid in the last 4 weeks, and respiratory tract infection within 8 weeks. smoking (min. 6 months) had asthma or other lung diseases, including obliterative bronchiolitis, bronchiectasis,and cystic fibrosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the value of fractional exhaled nitric oxide(FeNO) in patients with cough variant asthma | at least 4 weeks of treatment | FENO will be performed by using a hand-held portable machine (NIOX MINO, Aerocrine AB, Solna, Sweden) at a standard flow rate of 50 mL/s, in accordance with ATS/ERS recommendations. |
| the value of impulse oscillometry(IOS) in patients with cough variant asthma | at least 4 weeks of treatment | R5-R20（respiratory resistance）is measure by Jaeger MasterScreen Pulmonary |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the value of forced mid-expiratory flow (MMEF) in patients with cough variant asthma | at least 4 weeks of treatment | MMEF will be performed with a spirometer (Jaeger, Hoechberg, Germany) in accordance with the specifications and performance criteria recommended in the American Thoracic Society (ATS)/European Respiratory Society (ERS) Standardization of Spirometry |
| the value of BHR and fractional exhaled nitric oxide (FeNO) count in predicting response to asthma treatment | at least 4 weeks of treatment | MCH bronchial provocation tests will be performed with the Jaeger APS Pro system.Provocative dose causing a 20% fall in FEV1(PD20) will be recorded, and BHR is defined as present if PD20≤0.48 mg. FENO is measure by a hand-held portable machine(NIOX MINO, Aerocrine AB, Solna, Sweden) |
| the relationship between BHR and mid-expiratory flow | at least 4 weeks of treatment | BHR is measure by Jaeger APS Pro system.MMEF will be performed with a spirometer (Jaeger, Hoechberg, Germany) |
Countries
China
Outcome results
None listed